Skip to content
Screener

Kiniksa Pharmaceuticals International, plc KNSA Q2 2025 earnings

Reported July 29, 2025 · Before market open

Revenue$156.8MMiss by $9.7M
EPS$0.23Beat by $0.05
Revenue estimate$166.5M
EPS estimate$0.18

Next report

Oct 27, 2026 (in 3 months)
Revenue estimate$256.7M
EPS estimate$0.36

Financials

Q2 2025

Income statement

See full
Revenue$156.8M+44.3%
Gross profit$138.2M+43.5%
Operating income$20.2M+17,331%
Net income$17.8M+556%
EPS (diluted)$0.23+483%

Balance sheet

See full
Cash & equivalents$192.0M+93.4%
Total debt$9.8M-14.4%
Total equity$495.0M+13.8%
Total assets$661.2M+21.9%

Cash flow

See full
Operating cash flow$28.1M+444%
CapEx$165.0K—
Free cash flow$27.9M+440%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$2.12B+60.8%
Enterprise value$1.94B+57.5%
P/E442.7×—
P/S4×+0.1×

Profitability

See full
Gross margin85.9%-1.8pp
Operating margin0.8%+0.4pp
Net margin0.9%+0.5pp
FCF margin13%+4.0pp

Returns & leverage

See full
Return on equity1%+0.6pp
Debt / equity0×0.0×
Current ratio3.6×0.0×

Segments

By segment

See full
Pharmaceutical$156.8M+44.3%

By product

See full
Collaboration--100%

FAQ

When did Kiniksa Pharmaceuticals International, plc report Q2 2025 earnings?
Kiniksa Pharmaceuticals International, plc (KNSA) reported Q2 2025 earnings on July 29, 2025 before market open.
What were Kiniksa Pharmaceuticals International, plc's Q2 2025 revenue and EPS?
Kiniksa Pharmaceuticals International, plc reported revenue of $156.8M and eps of $0.23 for Q2 2025.
Did Kiniksa Pharmaceuticals International, plc beat estimates in Q2 2025?
Revenue missed the consensus estimate of $166.5M by $9.7M. EPS beat the consensus estimate of $0.18 by $0.05.
Where can I find Kiniksa Pharmaceuticals International, plc's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-071413) and the 10-Q periodic report (0001558370-25-009738) directly on SEC EDGAR. The filing index links above go to sec.gov.